Lymphokine preparations: a new approach to cancer immunotherapy
Papermaster, B.W.; Kaltenbach, M.L.
Missouri Medicine 75(12): 607-609; 612
1978
ISSN/ISBN: 0026-6620 PMID: 723839 Document Number: 125014
Document emailed within 1 workday
Related Documents
Mathé, G.; Halle-Pannenko, O.; Bourut, C. 1973: BCG in cancer immunotherapy: results obtained with various BCG preparations in a screening study for systemic adjuvants applicable to cancer immunoprophylaxis or immunotherapy National Cancer Institute Monograph 39(8): 107-113Marincola, F.M.; Da Pozzo, L.F.; Drucker, B.J.; Holder, W.D. 1990: Adoptive immunotherapy of human pancreatic cancer with lymphokine-activated killer cells and interleukin-2 in a nude mouse model Surgery 108(5): 919-929
Nii, A.; Sone, S.; Okubo, A.; Fawzy, F.; Yanagawa, H.; Ogura, T. 1987: Lymphokine-activated killer (LAK) adoptive immunotherapy: optimal method for large-scale LAK induction Gan to Kagaku Ryoho. Cancer and ChemoTherapy 14(6 Part 1): 1871-1876
Kanai, T.; Monden, M.; Takeda, T.; Gotoh, M.; Sakon, M.; Umeshita, K.; Hasuike, Y.; Sakita, I.; Nakano, H.; Yoshida, T. 1993: Adoptive immunotherapy in patients with multiple hepatic cancers using lymphokine activated killer cells (LAK) and interleukin-2 Gan to Kagaku Ryoho. Cancer and ChemoTherapy 20(11): 1457-1460
Schultz, R.M.; Chirigos, M.A. 1978: Similarities among factors that render macrophages tumoricidal in lymphokine and interferon preparations Cancer Research 38(4): 1003-1007
Marcus, S.L.; Dutcher, J.P.; Paietta, E.; Ciobanu, N.; Strauman, J.; Wiernik, P.H.; Hutner, S.H.; Frank, O.; Baker, H. 1987: Severe hypovitaminosis C occurring as the result of adoptive immunotherapy with high-dose interleukin 2 and lymphokine-activated killer cells Cancer Research 47(15): 4208-4212
Shiloni, E.; Lafreniere, R.; Mulé, J.J.; Schwarz, S.L.; Rosenberg, S.A. 1986: Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice Cancer Research 46(11): 5633-5640
Bubeník, J.; Indrová, M.; Toulcová, A. 1986: Immunotherapy of murine sarcomas with interleukin 2. I. Local administration of human recombinant IL-2 preparations Folia Biologica 32(6): 384-391
Spinozzi, F.; Cimignoli, E.; Broccucci, L.; Gerli, R.; Cernetti, C.; Rambotti, P. 1991: Immunotherapy in allergic diseases. Evaluation of short-term efficacy of aluminum hydroxide-absorbed slow-release preparations La Clinica Terapeutica 136(4): 245-251
Ghanta, V.K.; Hiramoto, N.S.; Solvason, H.B.; Soong, S.J.; Hiramoto, R.N. 1990: Conditioning: a new approach to immunotherapy Cancer Research 50(14): 4295-4299
Wallack, M.K. 1977: A new approach in immunotherapy with Vaccinia oncolysates Surgical Forum 28: 160-161
Richman, S.P.; Mavligit, G.M.; Wolk, R.; Gutterman, J.U.; Hersh, E.M. 1975: Epilesional scarification. Preliminary report of a new approach to local immunotherapy with BCG JAMA 234(12): 1233-1235
Yamasaki, T.; Kikuchi, H. 1989: An experimental approach to specific adoptive immunotherapy for malignant brain tumors Nihon Geka Hokan. Archiv für Japanische Chirurgie 58(6): 485-492
Minev, B.R.; Guo, F.; Gueorguieva, I.; Kaiser, H.E. 2002: Vaccines for immunotherapy of breast cancer and prostate cancer: new developments and comparative aspects In Vivo 16(6): 405-415
Chiriva-Internati, M. 2011: Sperm protein 17: clinical relevance of a cancer/testis antigen, from contraception to cancer immunotherapy, and beyond International Reviews of Immunology 30(2-3): 138-149
Bereznaya, N.M.; Chekhun, V.F. 2007: Expression of CD40 and CD40L on tumor cells: the role of their interaction and new approach to immunotherapy Experimental Oncology 29(1): 2-12
Takeda, T.; Nakamura, K.; Sato, M.; Takeda, T.; Tomimaru, Y.; Takeda, H. 2014: The effect of immunotherapy and hyperthermia on patients with advanced or recurrent cancer - analyses by cancer type and recurrence form Gan to Kagaku Ryoho. Cancer and ChemoTherapy 41(10): 1261-1263
Papermaster, B.W.; Holtermann, O.A.; Rosner, D.; Klein, E.; Dao, T. 1974: Regressions produced in breast cancer lesions by a lymphokine fraction from a human lymphoid cell line Research Communications in Chemical Pathology and Pharmacology 8(2): 413-416
Stewart, J.A.; Belinson, J.L.; Moore, A.L.; Dorighi, J.A.; Grant, B.W.; Haugh, L.D.; Roberts, J.D.; Albertini, R.J.; Branda, R.F. 1990: Phase i trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer Cancer Research 50(19): 6302-6310
Sondel, P.M.; Hank, J.A.; Kohler, P.C.; Chen, B.P.; Sosman, J. 1989: "Lymphokine activated killing" as treatment for human cancer: clinical extrapolations from laboratory studies with interleukin-2 expanded leukocytes Progress in Clinical and Biological Research 288: 151-160